GlaxoSmithKline (GSK) has reported positive results from the open-label DREAMM-2 clinical trial of belantamab mafodotin in patients with multiple myeloma.

Belantamab mafodotin is a humanised immunoconjugate that targets B-cell maturation antigen (BCMA).

DREAMM-2 evaluated 2.5mg/kg and 3.4mg/kg every three weeks in heavily pre-treated patients with actively progressing multiple myeloma even after treatment with the current standard of care.

The trial enrolled patients who had a median of seven previous lines of therapy, were refractory to an immunomodulatory medicine and a proteasome inhibitor, and were refractory and/or intolerant to an anti-CD38 antibody.

Participants experienced a 31% overall response rate (ORR) with the 2.5mg/kg regimen. The company also reported that overall survival in subjects with a response was not reached in the six month follow-up period.

The safety and tolerability profile of the drug was consistent with previous findings. The most common Grade 3 or 4 adverse events relating to the 2.5mg/kg dose were keratopathy, thrombocytopenia and anaemia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GSK chief scientific officer and R&D president Dr Hal Barron said: “Patients with multiple myeloma whose disease has progressed despite currently available therapy have limited options and poor outcomes.

“Data from the DREAMM-2 study show that, if approved, belantamab mafodotin could offer an important new treatment option for these patients.”

The company submitted a biologics license application to the US Food and Drug Administration (FDA) for the approval of 2.5mg/kg belantamab mafodotin to treat relapsed or refractory multiple myeloma patients who previously received an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

If approved, the drug is expected to be the anti-BCMA agent accessible in the US.

GSK is also studying the drug as third-line monotherapy in relapsed/refractory multiple myeloma, as well as in combination with standard and new therapies in the first and second line setting.